Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost
Main Authors: | Davide Cao, George Dangas, Roxana Mehran |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-02-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.120.019889 |
Similar Items
-
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
by: Giulia Magnani, et al.
Published: (2021-02-01) -
Individual acute-phase bleeding and thrombotic risk balance assessment in patients undergoing percutaneous coronary intervention for acute myocardial infarction
by: Yohei Sotomi, et al.
Published: (2023-04-01) -
Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
by: Sukhdeep S. Basra, et al.
Published: (2018-06-01) -
Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75–100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study
by: Jiannan Li, et al.
Published: (2020-08-01) -
The effect of aspirin therapy on the plasma renin activity in myocardial infarction
by: M.H Ansari, et al.
Published: (1995-07-01)